Last updated: March 13, 2026
What is the Drug NDC 23155-0735?
NDC 23155-0735 is the Voretigene Neparvovec-rzyl (Luxturna), developed by Spark Therapeutics. It is a gene therapy approved by the FDA in December 2017 for treatment of inherited retinal disease caused by confirmed biallelic RPE65 mutation-associated retinal dystrophy. It is administered via subretinal injection and is designed to restore functional vision.
Market Size and Demand Drivers
Patient Population
- Estimated prevalence of RPE65 mutation-associated retinal dystrophy: approximately 1,000 to 1,200 patients in the U.S.
- Patients are typically diagnosed between 10-30 years of age.
- Market penetration depends heavily on early diagnosis, which remains limited.
Competitors and Alternatives
- Currently, Voretigene Neparvovec-rzyl is the only FDA-approved gene therapy for RPE65-related retinal dystrophy.
- No direct competitors approved; off-label use or other experimental treatments exist but lack regulatory approval.
Clinical Adoption and Usage Rates
- Initial uptake has been slow, owing to high treatment cost, limited awareness, and logistical challenges of administering gene therapy.
- Estimated annual treatment volume: 150–200 patients in the U.S. (2023), with potential growth as awareness increases.
- Applied standards suggest expansion as diagnostic rates improve, with global markets possibly adding 50% to US figures.
Price Analysis and Revenue Projections
Current Pricing
- List price for Voretigene Neparvovec-rzyl approximates $425,000 per eye (per 2018 FDA pricing data).
- Total cost per patient for bilateral treatment: roughly $850,000 for both eyes.
- Payers commonly negotiate significant discounts, but list price remains a benchmark.
Revenue Estimates (2023-2028)
| Year |
Estimated Patients Treated |
Total Revenue (USD) |
Assumptions |
| 2023 |
150 |
$127.5 million |
Slow adoption; awareness remains limited |
| 2024 |
180 |
$153 million |
Slight increase due to improved diagnosis |
| 2025 |
220 |
$187 million |
Growing physician familiarity |
| 2026 |
275 |
$233.75 million |
Market penetration accelerates |
| 2027 |
325 |
$276.25 million |
Expanded access, more treatments |
| 2028 |
375 |
$318.75 million |
Broader use, price negotiations ongoing |
Pricing Sensitivity
- Price flexibility is constrained by regulatory, payer, and manufacturing factors.
- Price discounts in managed care and government programs could reduce realized revenue by 20-30%.
Cost Considerations
- Manufacturing costs estimated around $50,000-$100,000 per dose (per independent analyses).
- Distribution, administration, and monitoring costs add significantly, supporting high pricing justified by complexity and rarity.
Factors Influencing Future Pricing and Market Penetration
- Regulatory updates: New indications or expanded patient populations could increase demand.
- Cost negotiations: Managed care entities and government programs may limit reimbursement levels.
- Market expansion: Regulatory approvals outside the U.S. (EU, Asia) could substantially grow revenue streams.
- Healthcare infrastructure: Limited availability of specialized centers impacts accessibility.
Market Challenges
- High development and manufacturing costs restrict price reductions.
- Slow diagnosis and logistical barriers impede rapid adoption.
- Competition from emerging gene therapies targeting other retinal dystrophies could influence prices.
Summary
NDC 23155-0735 (Luxturna) commands high pricing due to its rarity, complexity, and innovation status. Revenue projections suggest steady growth, contingent upon increased awareness, expanded access, and acceptance by healthcare systems.
Key Takeaways
- The therapy's high list price (~$425,000 per eye) results in potential revenues approaching $300 million annually in the US alone by 2028.
- Market growth depends on diagnosis rates, geographical expansion, and payer negotiations.
- Limited competitors safeguard market share but do not guarantee significant price increases.
- Manufacturing and distribution costs are substantial, supporting the premium pricing model.
- Future developments may include additional indications or formulations altering the market landscape.
FAQs
1. What are the clinical benefits of Voretigene Neparvovec-rzyl?
It restores vision in patients with RPE65 mutation-associated retinal dystrophy, improving navigation, object recognition, and overall visual function in some cases.
2. How is the price of Luxturna determined?
It reflects R&D costs, manufacturing complexity, rarity of condition, and the value of restored vision. Payor negotiations can significantly lower actual reimbursement.
3. What is the size of the treated patient population?
Estimated at 1,000–1,200 patients in the U.S., with potential additional cases globally as diagnosis improves.
4. How might market access evolve?
As awareness increases and infrastructure improves, more patients are expected to receive treatment, potentially increasing revenue by 50% or more.
5. Are there ongoing initiatives to expand the therapy's approval?
Yes, clinical trials are exploring broader indications. Regulatory agencies may consider expanded approvals based on ongoing research.
References
[1] Food and Drug Administration. (2017). FDA approves first gene therapy for inherited retinal disease. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-inherited-retinal-disease
[2] Bloomberg Industry Group. (2022). Gene therapy market reports.
[3] Spark Therapeutics. (2018). Luxturna prescribing information.
[4] IQVIA. (2022). Market report on rare disease therapeutics.
